Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral flecainide crossover trial in catecholaminergic polymorphic ventricular tachycardia
2011-001287-22Phase 2Completed
- Sponsor
- Fondazione Salvatore Maugeri
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of flecainide in catecholaminergic polymorphic ventricular tachycardia (CPVT) (2 arms), sponsored by Fondazione Salvatore Maugeri. Primary endpoint: Ventricular tachycardia treated by implantable cardioverter-defibrillator or death. Started Mar 2012; status: completed.
02
Drugs
flecainide
03
Conditions
catecholaminergic polymorphic ventricular tachycardia (CPVT)
Beyond the preview
Go deeper on 2011-001287-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001287-22.